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ONLINE METHODS
Cohort description
The consortia participating in MAGIC contributed a maximum total of 122,743
individuals.  The Stage 1 discovery set included 36,466-46,186 individuals (depending on trait), 
from 17 population-based cohort studies and four case-control studies.  The Stage 2 replication 
set included up to 76,558 individuals from 33 sample collections, including 28 population-based 
and five case-control collections.  Detailed information on all studies is provided in 
Supplementary Tables 1a (Stage 1 discovery) and 1b (Stage 2 replication).  All participants were 
adults of white European ancestry from the United States or Europe.  Individuals were excluded 
from the analysis if they had a physician diagnosis of diabetes, were on diabetes treatment (oral 
or insulin), or had a fasting plasma glucose equal to or greater than 7 mmol/L.  Some individuals 
with FG <7 mmol/L but who would have tested abnormally after an oral glucose challenge could 
have been included; we estimated this number to be as low as <1% in Framingham and 1.6% in 
Inter99, two population cohorts in which all relevant data were available.  Individual studies 
applied further sample exclusions, including pregnancy, non-fasting individuals, type 1 diabetes, 
outliers ±3 SD of distribution for either FG or FI, as detailed in Supplementary Table 1a and 1b.  
Individual Stage 1 discovery cohort sizes ranged between 458 and 6,479 samples; Stage 2 
replication cohorts ranged between 554 and 8,010 samples.  All studies were approved by local 
research ethic committees and all participants gave informed consent.
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Type 2 diabetes association
The association analysis of lead SNPs with T2D as a dichotomous trait was carried out 
under the additive genetic model in 27 case-control cohorts totaling 40,655 cases and 87,022 
controls of European descent.  These included 8,130 cases and 38,987 controls from eight 
DIAGRAM+ Consortium studies and 32,525 additional T2D cases and 48,035 additional controls 
from 19 cohorts genotyped de novo, listed as cohort (N cases/N controls): FUSION_stage2 
(1,203/1,261), METSIM_CC (854/3,469), Addition/Ely (892/1,612), Cambridgeshire Case Control 
Study (541/527), Norfolk Diabetes Case Control Study (6,056/6,428), deCODE (1,465/23,194), 
DGDG (690/730), DGI (1,022/1,075), ERGO (1,178/4,761), EUROSPAN (268/3,710), FUSION 
(1,161/1,174), KORA S3 (433/1,438), T2D Wellcome Trust Case Control Consortium 
(1,924/2,938), HPFS (1,146/1,241), Nurses’ Health Study (1,532/1,754), Danish (3,652/4,992), 
KORA_replication consisting of cases from KORAS1-S4 and the Augsburg Diabetes Family Study 
(ADFS) and controls from KORA S4 (1,047/1,491), OxGN_58BC (UKRS2) (612/1,596), UKT2DGC 
(4,979/6,454), Framingham Heart Study_CC (674/7,664), NHANES (289/1,219), Partners/Roche 
(534/649), Umeå (1,327/1,424), French_CC (2,155/1,862), GCI Poland_DGI_Stage2 (969/969), 
GCI_US_DGI_Stage2 (1,191/1,171), and MDC_MDR_DGI_Stage2 (2,814/3,234).  According to 
the best sample-specific model in some cohorts, age and BMI were used as covariates for 
adjustment of the case-control association.  The meta-analysis of the cohort-specific summary 
statistics (odds ratios and 95% confidence intervals) was performed using a fixed effects 
inverse-variance approach with GWAMA (http://www.well.ox.ac.uk/gwama/index.shtml).
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Quantitative trait measurements
Fasting glucose (FG, in mmol/L) was measured from fasting whole blood, plasma or 
serum or a combination of these.  Whole blood FG levels were corrected to plasma FG using a 
correction factor of 1.13.  Fasting insulin was measured as described in Supplementary Tables 
1a and 1b for each of the cohorts.  Indices of β-cell function (HOMA-B) and insulin resistance 
(HOMA-IR) were derived from paired fasting glucose and insulin measures using the 
homeostasis model assessment18.
Genotyping, imputation and quality control
Genotyping of individual cohorts was carried out using commercial genome-wide arrays 
as detailed in Supplementary Tables 1a and 1b.  For genome-wide SNP sets, different criteria 
were used to filter out poor-quality SNPs and samples prior to imputation.  Criteria generally 
applied for exclusion of samples were:  (i) call-rate <0.95, (ii) individuals with heterozygosity 
outside the population-specific bounds and (iii) ethnic outliers.  Criteria generally applied for 
exclusion of SNPs were:  (i) minor allele frequency (MAF) <0.01, (ii) Hardy-Weinberg equilibrium 
P <10-4 or 10-6 and (iii) call-rate <0.95.  Imputation of additional autosomal SNPs from the 
HapMap CEU reference panel was performed using the software MACH23, IMPUTE22 or 
BIMBAM68 with parameters and pre-imputation filters as specified in the Supplementary Tables 
1a and 1b.  SNPs were also excluded if the cohort-specific imputation quality as assessed by 
r2.hat<0.3 (MACH) or proper-info<0.4 (IMPUTE) or observed/expected dosage variance <0.3 
(BIMBAM), or if their mapping and/or strand annotation was ambiguous.  In total, up to 2.5 
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million genotyped or imputed autosomal SNPs were considered for meta-analysis.  SNPs were 
considered for meta-analysis if they were available for at least 20% of maximum available 
sample size, or ≥10,000 individuals informative for each SNP.
Statistical analyses
We excluded from analysis people with diabetes (those on diabetes treatment or with 
FG ≥7 mmol/L), non-fasting participants and pregnant women.  In each cohort we used log-
transformed trait values for FI, HOMA-IR and HOMA-B and untransformed FG as the dependent 
variable in linear regression models that included terms for sex, age (except NFBC 1966, where 
all subjects were 31 years old), study site (if applicable), geographical covariates (if applicable) 
and age squared (Framingham only) to assess the association of additively coded genotypes 
with trait values.  Association testing was performed using software that takes genotype and 
imputation uncertainty into account, using a missing data likelihood test implemented in 
SNPTEST22 or by using allele dosages in the linear regression model in MACH2QTL23, GenABEL69
or lmekin from the R kinship package70.  Regression estimates for the effect of the additively 
coded SNP were pooled across studies in a meta-analysis using a fixed effect inverse-variance 
approach71. The individual cohort results, but not the final meta-analysis results, were 
corrected for residual inflation of the test statistic using the genomic control method72. Final GC 
values were 1.05 for FG, 1.046 for HOMA-B, 1.04 for HOMA-IR and 1.041 for FI.
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Replication SNP selection and analysis
Twenty-five lead SNPs from among the most significant association results in the Stage 1 
discovery meta-analyses were selected for replication.  In order to account for the correlation 
between traits and to ensure independent signals, highly significant associations detected in 
two or more traits were selected only once.  All selected loci had an r2<0.5 with the nearest 
other selected loci.  From each unique locus, the SNP with the smallest P value was chosen.  All 
SNPs had a minimum sample size of at least 80% of the overall discovery sample.  Variants 
known to be associated with T2D (i.e. SLC30A8, TCF7L2) and reaching the genome-wide 
significance threshold (P<510-8) were not included in the replication list.  SNPs were also 
selected on the basis of low heterogeneity between studies, although loci with biologic 
plausibility were selected even if there was some evidence of heterogeneity.  Seventeen SNPs 
from the glucose and HOMA-B analyses and 8 SNPs from the insulin and HOMA-IR analyses 
were taken for Stage 2 replication.  Although previously described, variants in G6PC2, GCK, 
GCKR and MTNR1B were selected for replication to serve as “positive controls” in all study 
samples.  Up to 4 alternate proxy SNPs (maximizing LD with the index SNP) were selected for 
each locus to accommodate the capacities of different platforms.  In the cases where index 
SNPs failed in the initial stage of genotyping, replication results were obtained for proxy SNPs in 
strong LD with the original index SNP whenever possible.  SNPs with Hardy-Weinberg 
equilibrium P-values ≤0.001 were excluded.  In cases where more than one proxy SNP was 
genotyped but the index SNP was unavailable, the proxy SNP’s LD with the index SNP and its 
call rate was used to select the SNP with the best quality genotyping to be included in the meta-
analysis.
MAGIC 2
45
Genotype data for 25 signals or proxies were obtained from 33 independent replication 
cohorts, including both in silico data from pre-existing GWAS (8) and de novo genotyping (25).  
Phenotype definition and association testing between fasting traits and these 25 SNPs was 
performed in the same manner in each cohort.  The inverse variance method was then applied 
to derive pooled effect estimates from the Stage 2 replication samples using METAL 
(http://www.sph.umich.edu/csg/abecasis/Metal/index.html) and GWAMA software.  We then 
carried out a pooled analysis of the Stage 1 discovery cohorts and Stage 2 replication samples 
to determine which SNPs reached genome-wide significance, as determined by a P <510-8.  
Heterogeneity was assessed using the I2 index48.
Notes on replication genotyping
Amish
The Amish trait data is reported for the Heredity and Phenotype Interaction Heart Study 
(HAPI), Amish Family Longevity Study (LS), and Amish Family Diabetes Study (AFDS).  All studies 
genotyped 15 SNPs (rs10830963, rs4607517, rs11605924, rs11708067, rs1416802, rs588262, 
rs4675095, rs6947696, rs4912494, rs11920090, rs174550, rs7034200, rs4243291, rs457420,
rs1881413).  Other SNPs were typed on different sample subsets: AFDS only (rs2191349, 
rs10493846); HAPI only (rs560887); HAPI, LS, and Pharmacogenomics of Anti-Platelet 
Interaction study (PAPI) (rs780094, rs6479526, rs340835, rs11167682); HAPI, LS, AFDS, PAPI 
(rs4918635, rs855228); HAPI, LS, Amish Family Calcification Study (rs11039149). The genotyping 
statistics in Supplementary Table 1b are reported for the AFDS + HAPI + LS cohorts. 
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FUSION stage 2 
The FUSION stage 2 cohort includes some Health 2000 samples, none of which overlap 
with the Health 2000 cohort.
SNP score
For the 16 SNPs reaching genome-wide significance of association (in either the 
discovery stage alone or in the combined replication and discovery meta-analysis), we defined a 
risk score as the weighted sum of the number of expected risk alleles, where the sum of the 
weights was set to the number of SNPs (16) and the weights were proportional to the estimate 
of the effect size for each SNP.  Mean fasting glucose levels according to the number of 
weighted risk alleles were computed in some of the largest cohorts (Framingham, ARIC, NFBC 
1966) with all 16 SNPs available (genotyped or imputed).
Bioinformatic analysis and functional annotation
To perform a preliminary assessment of the underlying functionality at the associated 
loci, we first expanded the set of SNPs to include those in strong LD with the index SNP (defined 
as pairwise r2 >0.8 according to HapMap Phase II CEU data).  We then mapped the genomic 
locations of all the SNPs in this expanded set to several non-mutually-exclusive genomic 
annotation sets: non-synonymous sites, splice sites, intergenic regions, 5’ UTR, 3’ UTR and 
introns from dbSNP version 129 (http://www.ncbi.nlm.nih.gov/projects/SNP/); 1kb and 5kb 
regions upstream of transcription start sites from Ensembl version 49 
(http://www.ensembl.org); intergenic predicted transcription factor binding sites, CpG islands, 
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ORegAnno elements, Encode region ancestral repeats, EvoFold elements, multi-species 
conserved sequences and positively selected gene regions from the University of California 
Santa Cruz human table browser (http://genome.ucsc.edu/cgi-bin/hgTables); predicted 
microRNA target sites from TargetScan 4.2 (http://www.targetscan.org); validated enhancers 
from the Vista Enhancer Browser (http://enhancer.lbl.gov); predicted cis-regulatory modules 
from the PreMod database (http://genomequebec.mcgill.ca/PreMod) and validated non-coding 
RNAs from  RNAdb (http://research.imb.uq.edu.au/rnadb/).  The potential functional effect of 
non-synonymous substitutions were evaluated using three prediction programs: SIFT 
((http://blocks.fhcrc.org/sift/SIFT.html), PolyPhen (http://genetics.bwh.harvard.edu/pph/), and 
PANTHER (http://www.pantherdb.org/tools/csnpScoreForm.jsp).
GRAIL
We used GRAIL (Gene Relationships Across Implicated Loci, 
www.broad.mit.edu/mpg/grail) to examine the putative relationship between candidate genes 
at validated loci based on concomitant appearance in published scientific text.  GRAIL is a 
bioinformatic annotation tool that, given several genomic regions or SNPs associated with a 
particular phenotype or disease, searches for similarities in the published scientific text among 
the associated genes (Raychaudhury et al, submitted).  It scores regions for functional 
relatedness by defining associated regions based on the interval between recombination 
hotspots flanking furthest neighbouring SNPs with r2>0.5 to the index SNP, and identifies 
overlapping genes in that region.  Based on textual relationships between genes (as determined 
from a download of Pubmed abstracts on December 16, 2006), GRAIL assigns a P-value to each 
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region suggesting its degree of functional connectivity, and picks the best candidate gene after
taking into account multiple comparisons.
We considered the following SNPs and candidate genes: rs10830963 (MTNR1B), 
rs2191349 (DGKB), rs4607517 (GCK), rs11920090 (SLC2A2), rs11708067 (ADCY5), rs560887 
(G6PC2) ,  rs780094 (GCKR), rs11605924 (CRY2), rs7034200 (GLIS3), rs340874 (PROX1), 
rs10885122 (ADRA2A), rs7944584 (NR1H3), rs174550 (FEN1, FADS1, C11orf9, C11orf10, FADS2), 
and rs11071657 (FAM148B).  In addition, the following keywords describing functional 
connections were used: “glucose”, “diabetes”, “islet”, “diacylglycerol”, “circadian”, “insulin”, 
“drosophila”, “liver”, “clock”, “cyclase”, “pancreatic”, “adenylyl”, “memory”, “beta”, “mice”, 
“islets”, “phosphatase”, “camp”, “light”, “activity”.  A total of 7 genes (MTNR1B, DGKB, GCK, 
SLC2A2, ADCY5, G6PC2 and GCKR) out of 14 had a significant  association with functional 
connectivity (at P<0.1) compared to 1.4 expected under the null, demonstrating that this gene 
set is enriched in relationships with each other.
eQTL analysis
The validated association signals were searched for previous evidence of expression 
quantitative trait loci (eQTLs) using several data sources.  Liver eQTL association results were 
obtained from Schadt et al.39.  Cortex eQTL association results were obtained from Myers et 
al.40.  Epstein-Barr virus-transformed lymphoblastoid cell eQTLs from 41 were retrieved using 
the mRNA by SNP browser (http://www.sph.umich.edu/csg/liang/asthma/).  For each region, 
we limited our analysis to cis eQTLs given the difficulty of reliably interpreting trans effects.  
Genes or SNPs within 1 MB from the lead SNP were considered.  The r2 values between the lead 
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SNPs and eQTL SNPs were retrieved from the HapMap Phase 2 data (CEU Panel), and only SNPs 
with r2 >0.6 were considered. 
Of the 12 SNPs showing association with liver and located at < 1 MB from the lead SNP, 
5 had no r2 data in HapMap and were located at large distances from the MAGIC lead SNP 
(mean 320 Kb, range 48-725 Kb).  Of the remaining 7, rs174548 at the FADS1 (fatty acid 
desaturase 1, PeQTL = 1.74 x 10-5) locus was located 130 bp away from the lead SNP rs174550 
and in strong LD (pairwise r2 = 0.8).  All the remaining SNPs did not fit our criteria for selection, 
although we note that a second lead SNP (rs780094 at GCKR) was also moderately associated 
(r2=0.49, distance = 74 Kb) with a strong effect eQTL (rs4665969 at IFT172, PeQTL = 3.97 x 10-23).  
For circulating lymphoblastoid cells, the only cis effect fitting our criteria was observed for the 
MAGIC SNP rs174550 (FADS1), which was located 24 Kb from a known eQTL centered on the 
FADS2 gene (PeQTL = 3.1 x 10-4).  Finally, for cortex, the only eQTL was found at four SNPs within 
LOC131076 (rs6769837, rs7648255, rs12636058, rs6438726), all located >870 Kb from the 
MAGIC lead SNP (rs11708067 at ADCY5, LD metrics not available).
Gene expression studies
Adult total RNA samples, except pancreatic islets and flow-sorted β cells, were 
purchased from Clontech (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France).  Adult 
human islets (n=2) were available through existing collections at Oxford University and were 
obtained with full ethical consent.  Flow-sorted β cells were obtained from two adult brain-
dead donors (preparations >92% insulin-positive cells), in accordance with French legislation 
and the local ethical committee, as previously described73.
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Tissue panel (Oxford): Samples were treated with DNase 1 (Ambion) to ensure that residual
genomic contamination was removed.  For each tissue, 1 g of total RNA was used to generate 
cDNA by random primed first strand synthesis (Applied Biosystems) according to the 
manufacturer’s protocol.  Reverse transcription was also performed on all samples in the 
absence of the enzyme reverse transcriptase, and these samples were used as negative 
controls.  Primers were designed to cover all RefSeq transcripts. Resulting cDNA for each tissue 
was diluted 1:100 and 4 l used in a 10 l qRT-PCR reaction with 5.5 l gene expression 
mastermix (Applied Biosystems) and 0.5 l gene specific assay (Applied Biosystems).  All 
samples were run in triplicate.  A standard curve was generated by pooling 1 l of each cDNA 
and serially diluting (1:50, 1:100, 1:200, 1:400, 1:800) and running as above.  Expression levels 
were determined with respect to the mean of 4 endogenous controls (β-actin, B2M, HPRT, 
TOP1) and normalizing to the mean of the 1:100 standard for the assay of interest.  For ease of 
presentation the maximum gene expression has been equalled to 1 and all other tissue 
expressions reported as a fraction of this. 
Tissue panel (Cambridge): Adult human total RNA samples (cerebellum, cortex, spleen, 
pancreas, lung, kidney, liver, skeletal muscle, heart, testes, adipocyte and total brain) were 
obtained from Clontech.   Random-primed first-strand cDNA synthesis was performed with 100 
ng RNA using Super Script II (Invitrogen) according to manufacturer’s instructions.  Primers 
were design to cover the majority of protein coding transcripts. For the standard curve 200 ng 
of a pool of all RNA samples was amplified using the same protocol.  The resulting cDNA for 
each tissue was diluted five-fold and 5 l of each sample were used in a 12 l SYBR Green PCR 
Master Mix (Applied Biosystem).  The cDNA for the standard curve was diluted two-fold and 
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used as above.  Primers (SIGMA) were designed to anneal to all annotated isoforms of any given 
gene.  Quantitative PCR reactions were done in triplicate on an ABI 7900HT (Applied 
Biosystems).  Expression levels were calculated from their average crossing points, expressed 
relative to the control gene Top1 (Topoisomerase 1), and normalized to gene-specific 
expression in pancreas.  For the purpose of presentation for each gene the maximal expression 
was equalled to one and the rest reported as fraction of this number.  The results of these 
duplicate experiments, which largely confirm those reported in the text, are shown in 
Supplementary Figure 3.
Flow-sorted β cells (Lille): Samples were treated with DNase 1 (Ambion) to ensure that residual 
genomic contamination was removed.  For each tissue, 1 g of total RNA was used to generate 
cDNA by random primed first strand synthesis (Applied Biosystems) according to the 
manufacturer’s protocol.  Reverse transcription was also performed on all samples in the 
absence of the enzyme reverse transcriptase, and these samples were used as negative 
controls.  Total RNA was extracted using Nucleospin RNA II kit (Macherey Nagel) according to 
the manufacturer’s instructions.  Resulting cDNA for each tissue was diluted 1:10 and 4 l used 
in a 20 l qRT-PCR reaction with 10 l gene expression mastermix (Applied Biosystems) and 1 l 
gene specific assay (Applied Biosystems).  Data is presented as the most expressed gene (GLIS3) 
normalized to one and all other genes reported as a fraction of this number.
